=Cerus (CERS) reported earnings on Thur 3 Nov 2016 (a/h)

Cerus beats by $0.03, beats on revs; guides FY16 revs in-line  :

• Reports Q3 (Sep) loss of $0.14 per share, $0.03 better than the Capital IQ Consensus of ($0.17); revenues rose 27.5% year/year to $10.2 mln vs the $9.82 mln Capital IQ Consensus.
• Co issues in-line guidance for FY16, sees FY16 revs of $37-40 mln vs. $38.61 mln Capital IQ Consensus Estimate.
• "Beyond platelets and plasma, we are also moving forward with activities related to our red cell program, with plans to submit for European CE Mark approval and to initiate a U.S. Phase III trial."